CASPIAN and IMpower133: Comparing Frontline Trials in Extensive-Stage SCLC

This episode, "CASPIAN and IMpower133: Comparing Frontline Trials in Extensive-Stage SCLC," features the panel walking through the two trials that put checkpoint inhibitors on the map in this setting.

The panel walks through the two pivotal trials that established checkpoint inhibitors as frontline therapy in extensive-stage small cell lung cancer. The first, a randomized phase 3 trial with three arms, compared a platinum-etoposide chemotherapy backbone alone against that same backbone plus durvalumab, and against the backbone plus both durvalumab and tremelimumab. Adding durvalumab significantly improved median overall survival, from roughly 10.3 to 13 months, a difference the panel describes as modest-sounding but clinically meaningful given the field's history. Progression-free survival did not improve significantly, and adding the second immunotherapy agent, tremelimumab, provided no additional benefit over durvalumab alone.

A second global, randomized, double-blind trial evaluated atezolizumab, pairing platinum-etoposide induction with either atezolizumab or placebo maintenance after four induction cycles. As with the durvalumab trial, progression-free survival differences were modest, but overall survival improved by about two months, supporting FDA approval back in 2019. The panel recalls how significant that approval felt at the time, arriving after a long run of negative trials in this setting, even though the absolute benefit was small.

The episode closes on a practical comparison: the two trials allowed different chemotherapy backbones, one permitting a choice between carboplatin and cisplatin with either four or six cycles, the other built specifically around carboplatin-etoposide. The panel explains why this flexibility matters clinically, noting that having options in platinum choice and cycle number, along with differences in dosing schedules between the two immunotherapy agents, can simplify workflows for nursing, pharmacy, and prior authorization, particularly in community-based practices managing a high volume of patients.

In "CASPIAN at Three Years: Long-Term Survival in Extensive-Stage SCLC," the panel revisits one of these trials with a longer-term survival update.